Mounjaro Cost & Access in the US (2026)

If you search “how much does Mounjaro cost,” you’ll find numbers ranging from $25 to over $1,100 a month — and all of them are true, for different people. The spread isn’t pharmacy markup or a quirk of where you live. It comes from one fact that most cost guides bury: Mounjaro is the type 2 diabetes brand of tirzepatide. That label, not the molecule, is what decides which savings programs you can use, whether Medicare pays, and how your commercial plan treats the prescription.

This page walks the real 2026 cost picture for Mounjaro specifically. For the same molecule sold under its weight-management brand, see Zepbound cost in the US; for the molecule-level view across both brands, see the tirzepatide cost overview.

Note: Prices and program terms below are current as of June 2026 and change frequently. Treat them as a structure for understanding your options, not a quote. Confirm any figure with the pharmacy, Lilly, or your insurer before you rely on it.

The diabetes label is the lever

Mounjaro and Zepbound contain the same active ingredient — tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. The FDA approved them as two separate products: Mounjaro for type 2 diabetes (2022), and Zepbound for chronic weight management and obstructive sleep apnea (2023 onward). Clinically they behave the same way. Financially they behave very differently.

That matters because nearly every cost lever for Mounjaro is tied to the diabetes indication:

• The manufacturer savings card requires a prescription that matches Mounjaro’s FDA-approved use (type 2 diabetes).
• Medicare Part D can cover Mounjaro for diabetes — but federal rules block Medicare coverage of GLP-1 drugs prescribed purely for weight loss.
• Commercial insurers are far more likely to cover, and place on a friendlier formulary tier, a diabetes drug for a diabetic patient than a weight-loss drug for an off-label use.

So the honest answer to “what does Mounjaro cost” starts with two questions about you, not about the drug: do you have a type 2 diabetes diagnosis, and what kind of insurance do you carry?

The list price (and why almost nobody pays it)

Mounjaro’s list price — the wholesale acquisition cost, or sticker — is roughly $1,070–$1,110 for a 28-day supply (a carton of four single-dose pens) as of mid-2026. A useful detail: every dose strength carries the same list price. Moving to a higher strength over time doesn’t raise the sticker.

That list figure is what you’d face walking into a retail pharmacy with no insurance and no program. Very few people actually pay it. Standard discount cards like GoodRx shave only a modest amount off a patented, single-source drug — typically into the four figures still, around $900–$1,200 — because there’s no generic tirzepatide and won’t be while the patent holds. The real savings come from the channels below, almost all of which hinge on the diabetes label.

The Mounjaro Savings Card: the $25 route and its walls

For commercially insured patients, Eli Lilly’s Mounjaro Savings Card is the single biggest lever, and it works in two very different tiers:

• Covered tier — your commercial plan covers Mounjaro: you may pay as little as $25 per month, with the card capped around $150 per one-month fill (up to roughly $450 per three-month fill) and an annual ceiling near $1,950.
• Non-covered tier — you have commercial insurance but your plan doesn’t cover Mounjaro: the card sets a higher floor, often around $499 per fill, with a larger annual ceiling.

The card is a copay-reduction program that acts as a secondary payer at the counter — it is not insurance and not a coupon anyone can clip. It carries hard walls worth knowing before you count on the $25 figure:

• Commercial insurance only. Medicare, Medicaid, TRICARE, VA, and other government plans are excluded by federal anti-kickback law. There is no legitimate workaround.
• Indication-specific. The card terms tie to Mounjaro’s approved type 2 diabetes use. Using it against an off-label weight-loss prescription is where eligibility gets murky — ask your prescriber rather than assuming.
• Coverage must clear first. In the covered tier, the $25 price only applies after your plan approves the claim. If prior authorization isn’t in place yet, the card doesn’t rescue you — you’re paying close to full price until coverage lands.
• Time-limited. The current card program runs through the end of 2026; Lilly can change or end it.

Medicare and Medicaid: where the diabetes label pays off

This is the part of the Mounjaro story that genuinely diverges from the weight-loss brands. Because Mounjaro is a diabetes drug, Medicare Part D plans can cover it when it’s prescribed for type 2 diabetes and it sits on your plan’s formulary. By contrast, Medicare generally will not cover GLP-1 medications prescribed solely for weight loss — so Wegovy or Zepbound for obesity alone usually fall outside standard Part D coverage. A Medicare patient with diabetes is in a structurally better position on tirzepatide than a Medicare patient seeking it for weight loss.

The trade-off: Medicare patients can’t use the manufacturer savings card. Your out-of-pocket cost then depends on your specific plan’s deductible and cost-sharing. Two 2026 Medicare facts help here — the Part D deductible is capped (in the low-$600s), and once you hit the $2,100 annual out-of-pocket cap for covered drugs, the plan pays the rest of the year. For a high-cost drug taken every month, many diabetic patients reach that cap and then pay nothing further for covered medications.

Medicaid coverage of Mounjaro varies by state and typically tracks the diabetes indication as well.

Paying cash: LillyDirect self-pay and assistance

The cash landscape changed in 2026. Under an agreement between Eli Lilly and the federal government, Mounjaro was added to LillyDirect’s self-pay platform at 50–60% off the list price, putting manufacturer-direct cash pricing in the high-$400s per month rather than the four-figure sticker. That’s a meaningful drop for uninsured diabetic patients who don’t qualify for the savings card, and it comes straight from the manufacturer — no middleman and no question about authenticity.

For patients who can’t afford even that, the Lilly Cares Foundation patient assistance program can supply Mounjaro at no cost to qualifying uninsured or low-income patients who meet income and residency criteria. It’s assessed case by case and isn’t open to people with Medicare drug coverage.

If you don’t have diabetes, Mounjaro may be the wrong brand to price

Here’s the practical pivot that this page exists to make. If your goal is weight loss and you do not have type 2 diabetes, chasing Mounjaro on price usually works against you:

• The $25 savings card is built around the diabetes indication, so it may not apply cleanly to an off-label weight-loss script.
• Medicare won’t cover tirzepatide for weight loss regardless of brand.
• Commercial plans are more likely to deny an off-label diabetes drug than to evaluate the on-label weight brand.

In that situation, Zepbound is the on-label tirzepatide brand for weight management, and its LillyDirect self-pay vials are generally the cheaper cash route for the same molecule — frequently below Mounjaro’s self-pay price. The detailed Zepbound math, including the lower-cost vial tiers, lives on Zepbound cost in the US, and the head-to-head trade-offs are covered in Mounjaro vs Ozempic and the broader GLP-1 insurance coverage explainer. The rule of thumb: match the brand to your diagnosis, then price that brand — don’t pay for the wrong label.

What the price actually buys (and what to budget around)

The monthly drug figure is only part of the real cost of being on Mounjaro:

• The prescription itself — handled through a normal provider visit or a telehealth platform; because Mounjaro is FDA-approved, any licensed prescriber can write a standard, fillable brand prescription. (How to get tirzepatide in the US covers the access routes.)
• Labs and follow-up — diabetes management involves periodic monitoring; budget for visits, not just vials.
• Coverage friction — prior authorizations, step therapy, and appeals are common with GLP-1 drugs. Many initial denials are overturned on appeal with prescriber documentation, so a “no” isn’t always final.
• Continuity — this is a long-term medication, and program terms (savings card, self-pay pricing) can shift year to year, so the price you pay today isn’t guaranteed indefinitely.

How this could change in 2026 and beyond

The GLP-1 cost landscape is moving fast. The Lilly–government pricing agreement that put Mounjaro on self-pay also reshaped Medicare access for the weight-loss side of the family, and broader direct-to-consumer pricing keeps shifting — those developments are tracked in TrumpRx GLP-1 pricing. Patent dynamics, formulary decisions by individual insurers, and the arrival of oral GLP-1 options could all change what tirzepatide costs in either brand. For the bigger strategic picture of choosing and paying for a GLP-1, start with the complete GLP-1 weight-loss guide.

The throughline stays the same: with Mounjaro, the molecule is fixed but the price is not. Your diabetes diagnosis and your insurance type decide which of the very different prices above is yours.